COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    Relieving Chronic Itch
Previous Study | Return to List | Next Study

Relieving Chronic Itch: Oral Medication (CIPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02909569
Recruitment Status : Withdrawn (Contract could not be agreed on.)
First Posted : September 21, 2016
Last Update Posted : May 13, 2019
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
This study evaluates the effect of twice daily dose of INCB39110 in the treatment of itch in adults.

Condition or disease Intervention/treatment Phase
Pruritis Drug: INCB039110 Phase 2

Detailed Description:
Chronic idiopathic itch accompanies low-grade skin inflammation. These inflammatory features are associated with cytokine production which signal through the common JAK1-STAT pathway. It is therefore theorized that a selective JAK1 inhibitor such as INCB039110 may provide relief of itch symptom.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Relieving Chronic Itch : Oral Medication
Estimated Study Start Date : August 2018
Actual Primary Completion Date : October 9, 2018
Actual Study Completion Date : October 9, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Itching

Arm Intervention/treatment
Experimental: INCB039110
INCN039110 400 mg QD for 20 weeks. Subjects without clinical response after four weeks will increase to 600mg QD.
Drug: INCB039110
All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks.

Primary Outcome Measures :
  1. Numerical Rating Scale (NRS) itch score [ Time Frame: Baseline to 12 weeks ]
    Absolute change from Baseline NRS itch score to week 12

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and non-pregnant, non-lactating female subjects aged 18 years or older
  • Diagnosed with chronic idiopathic pruritus (CIP) with an NRS Itch Score of ≥ 7 at both Screening and Baseline
  • Diagnosis of CIP for at least 6 weeks prior to screening
  • Willingness to avoid pregnancy or fathering of children
  • Ability and willingness to provide written informed consent
  • Willing and able to comply with all study requirements and restrictions
  • Willing to not participate in any other interventional trial for the duration of their participation
  • Subjects must be in good health as determined by medical history, physical examination, electrocardiogram, clinical laboratory tests and vital signs
  • Failure of a course 2-week course of treatment with topical triamcinolone 0.1% ointment BID
  • Histopathological demonstration of skin dermal edema, eosinophils, mast cell activation or lymphocytic infiltration

Exclusion Criteria:

  1. Chronic pruritus due to a defined primary dermatologic disorder (e.g., atopic dermatitis, psoriasis, etc.)
  2. Patients with a prior diagnosis of excoriation disorder
  3. Use of topical treatments for CIP (other than bland emollients) within 1 week of baseline
  4. Systemic immunosuppressive or immunomodulating drugs (eg, oral or injectable corticosteroids, methotrexate, cyclosporine, mycophenolat mofetil, azathioprine) within 4 weeks of baseline
  5. Subjects with cytopenias at screening, defined as:

    1. Leukocytes < 3 × 109/L
    2. Neutrophils < lower limit of normal
    3. Lymphocytes < 0.8 × 109/L
    4. Hemoglobin < 10 g/dL
    5. Platelets < 100 × 109/L
  6. Unwilling or unable to follow medication restrictions or unwilling or unable to sufficiently washout from use of restricted medication
  7. Use of any prohibited medications (see Section 5.8) within 14 days or 5 half-lives (whichever is longer) of the baseline visit
  8. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal gastrointestinal, endocrine or metabolic dysfunction unless currently controlled and stable, including (but not limited to) the following:

    1. Positive for hepatitis C antibody test (anti-HCAbF) with detectable RNA
    2. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb);
    3. Positive for HIV (DUO test, p24 antigen)
  9. Active malignancy
  10. Subjects with a history of malignancy, except for the following adequately treated, nonmetastatic malignancies: basal cell skin cancer, squamous cell carcinomas of the skin, or in situ cervical cancer
  11. History (including family history) or current evidence of congenital long QT syndrome or known acquired QT prolongation
  12. Exposure to any investigational medication, including placebo, within 60 days of the Baseline Visit
  13. History of intolerance and/or hypersensitivity to medications similar to INCB039110 (e.g., Xeljanz)
  14. Participation in a previous INCB39110 trial
  15. Subjects with severely impaired liver function (Child-Pugh Class C) or end-stage renal disease on dialysis or at least 1 of the following:

    1. Serum creatinine > 1.5 mg/dL;
    2. Alanine aminotransferase or aspartate aminotransferase ≥ 1.5 × upper limit of normal
  16. Anyone affiliated with the site or sponsor and/or anyone who may consent under duress
  17. Any other sound medical reason as determined by the Investigator including any condition which may lead to an unfavorable risk-benefit of study participation, may interfere with study compliance or may confound study results
  18. Subjects taking potent systemic CYP3A4 inhibitors or fluconazole within 2 weeks or 5 half-lives, whichever is longer, before the baseline visit
  19. Subjects who have previously received JAK inhibitors, systemic or topical (e.g. ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib and pacritinib)
  20. Women who were pregnant or breastfeeding within 4 months before screening.
  21. Current or recent history (< 30 days before screening and/or < 45 days before randomization) of a clinically meaningful bacterial, fungal, parasitic, or mycobacterial infection
  22. Clinically significant or uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, and arrhythmia requiring therapy or uncontrolled hypertension (blood pressure > 150/90 mmHg) unless approved by medical monitor/sponsor
  23. History of alcoholism or drug addiction within 1 year before screening, or current alcohol or drug use that, in the opinion of the investigator, will interfere with the subject's ability to comply with the administration schedule and study assessments
  24. Subjects who have received systemic chemotherapy at any time
  25. Subjects who anticipate receiving a live or live-attenuated vaccination from screening through the final follow-up visit
  26. Subjects who, in the opinion of the investigator, are unable or unlikely to comply with the administration schedule and study evaluations


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02909569

Sponsors and Collaborators
Washington University School of Medicine
Layout table for investigator information
Principal Investigator: Brian Kim, MD/MTR Washington University School of Medicine
Layout table for additonal information
Responsible Party: Washington University School of Medicine Identifier: NCT02909569    
Other Study ID Numbers: CIP9110
First Posted: September 21, 2016    Key Record Dates
Last Update Posted: May 13, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases
Skin Manifestations